Wafae Iraqi
Issy-les-moulineaux, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe.
Journal: Patient preference and adherence
Published: December 21, 2023
The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: April 27, 2022
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
Journal: Oncology and therapy
Published: October 01, 2020
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Journal: Annals of hematology
Published: January 31, 2019
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Journal: Haematologica
Published: February 09, 2018
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
Journal: Journal of comparative effectiveness research
Published: August 03, 2017
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
Journal: PloS one
Published: May 28, 2015
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Journal: Journal of hepatology
Published: February 24, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026